Our Studies
Tenaya’s Research About Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
Tenaya Therapeutics is a clinical-stage biotechnology company using knowledge of genetics to discover and develop new medicines that may transform and extend the lives of people with heart disease.
Learn about Tenaya’s efforts to better understand and characterize ARVC due to PKP2 mutation, as well as the first clinical trial to study TN-401 as a potential treatment for ARVC due to PKP2 mutation.
A Phase 1b clinical trial of an investigational gene therapy called TN-401 for the treatment of ARVC caused by mutations in the PKP2 gene. All participants in this trial will receive the investigational treatment.
An antibody testing and natural history study designed to learn about who might be eligible for and benefit from an AAV-based gene therapy such as TN-401. No investigational treatments are given in this study.
Complete this form or contact patient.advocacy@tenayathera.com or clinical.trials@tenayathera.com for more information about:
- ARVC and genetic testing
- Where to take part in research for ARVC due to PKP2 mutation
- Tenaya’s science
